Heart and kidney protected in different patient groups

Approximately 40% of patients with type 2 diabetes mellitus (T2DM) develop diabetic kidney disease, which contributes to increased cardiovascular and mortality risk [1, 2]. This makes it all the more important to reduce renal risk in addition to blood glucose levels and cardiovascular risk. This is made possible by the broad use of an SGLT-2 inhibitor [3].